Generation and fluorescent formatting of aptamers targeting antiretroviral drugs (ARVs) for the detection of unreported ARV use on behalf of the CDC’s National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention Division of HIV Prevention.

The Centers for Disease Control and Prevention (CDC) is seeking a contractor to provide generation and fluorescent formatting of aptamers targeting antiretroviral drugs (ARVs) for the detection of unreported ARV use. The contractor will work with the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention Division of HIV Prevention to develop a high-throughput assay that leverages aptamer-based technologies and plate-based detection. The anticipated period of performance is two years, from August 3, 2026, to August 13, 2028. • The contractor will provide services to support the development of a high-throughput assay for ARV detection. • The assay will leverage aptamer-based technologies and plate-based detection. • The contractor will work with the CDC's Division of HIV Prevention Laboratory Branch. • The contract is for a two-year period, with an anticipated start date of August 3, 2026.